LT3107B - Transdermal therapeutical system containing fizostigmine and preparation the same - Google Patents
Transdermal therapeutical system containing fizostigmine and preparation the same Download PDFInfo
- Publication number
- LT3107B LT3107B LTIP1469A LTIP1469A LT3107B LT 3107 B LT3107 B LT 3107B LT IP1469 A LTIP1469 A LT IP1469A LT IP1469 A LTIP1469 A LT IP1469A LT 3107 B LT3107 B LT 3107B
- Authority
- LT
- Lithuania
- Prior art keywords
- layer
- transdermal therapeutic
- physostigmine
- therapeutic system
- adhesive
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title description 3
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 claims abstract description 34
- 239000000853 adhesive Substances 0.000 claims abstract description 12
- 230000001070 adhesive effect Effects 0.000 claims abstract description 12
- 239000013543 active substance Substances 0.000 claims abstract description 6
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims abstract 3
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 claims description 32
- 229960001697 physostigmine Drugs 0.000 claims description 32
- 239000010410 layer Substances 0.000 claims description 21
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 claims description 18
- 239000002253 acid Substances 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 9
- 239000003974 emollient agent Substances 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- 239000011241 protective layer Substances 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 230000007935 neutral effect Effects 0.000 claims description 6
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 5
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 claims description 4
- GOXQRTZXKQZDDN-UHFFFAOYSA-N 2-Ethylhexyl acrylate Chemical compound CCCCC(CC)COC(=O)C=C GOXQRTZXKQZDDN-UHFFFAOYSA-N 0.000 claims description 4
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical group CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 claims description 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 3
- 229920006243 acrylic copolymer Polymers 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical group CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 claims description 2
- 239000012790 adhesive layer Substances 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 229940055577 oleyl alcohol Drugs 0.000 claims description 2
- 230000002500 effect on skin Effects 0.000 claims 1
- 239000008240 homogeneous mixture Substances 0.000 claims 1
- 125000005641 methacryl group Chemical group 0.000 claims 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 claims 1
- 230000001681 protective effect Effects 0.000 abstract description 4
- 239000002861 polymer material Substances 0.000 abstract 2
- 239000004014 plasticizer Substances 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- GOQYKNQRPGWPLP-UHFFFAOYSA-N heptadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 10
- 229920000642 polymer Polymers 0.000 description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 150000001298 alcohols Chemical class 0.000 description 8
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 6
- BBMCTIGTTCKYKF-UHFFFAOYSA-N 1-heptanol Chemical compound CCCCCCCO BBMCTIGTTCKYKF-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- ZWRUINPWMLAQRD-UHFFFAOYSA-N nonan-1-ol Chemical compound CCCCCCCCCO ZWRUINPWMLAQRD-UHFFFAOYSA-N 0.000 description 6
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 6
- XGFDHKJUZCCPKQ-UHFFFAOYSA-N n-nonadecyl alcohol Natural products CCCCCCCCCCCCCCCCCCCO XGFDHKJUZCCPKQ-UHFFFAOYSA-N 0.000 description 5
- -1 oleic Chemical class 0.000 description 5
- IRGYNHLJUCOAOC-UHFFFAOYSA-N 2-octyloctadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCC(CO)CCCCCCCC IRGYNHLJUCOAOC-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 4
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 4
- 239000011888 foil Substances 0.000 description 4
- REIUXOLGHVXAEO-UHFFFAOYSA-N pentadecan-1-ol Chemical compound CCCCCCCCCCCCCCCO REIUXOLGHVXAEO-UHFFFAOYSA-N 0.000 description 4
- 229920000058 polyacrylate Polymers 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- KJIOQYGWTQBHNH-UHFFFAOYSA-N undecanol Chemical compound CCCCCCCCCCCO KJIOQYGWTQBHNH-UHFFFAOYSA-N 0.000 description 4
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 125000005397 methacrylic acid ester group Chemical group 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000005968 1-Decanol Substances 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- RZKSECIXORKHQS-UHFFFAOYSA-N Heptan-3-ol Chemical compound CCCCC(O)CC RZKSECIXORKHQS-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 150000004653 carbonic acids Chemical class 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- RHEVFAMQJMWLFS-UHFFFAOYSA-N icosan-2-ol Chemical compound CCCCCCCCCCCCCCCCCCC(C)O RHEVFAMQJMWLFS-UHFFFAOYSA-N 0.000 description 2
- 150000004667 medium chain fatty acids Chemical class 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- XMUJIPOFTAHSOK-UHFFFAOYSA-N undecan-2-ol Chemical compound CCCCCCCCCC(C)O XMUJIPOFTAHSOK-UHFFFAOYSA-N 0.000 description 2
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920000298 Cellophane Polymers 0.000 description 1
- 229930186657 Lat Natural products 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- ALSTYHKOOCGGFT-UHFFFAOYSA-N cis-oleyl alcohol Natural products CCCCCCCCC=CCCCCCCCCO ALSTYHKOOCGGFT-UHFFFAOYSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 231100000223 dermal penetration Toxicity 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- ONNSSMGRFLULCC-UHFFFAOYSA-N icosan-9-ol Chemical compound CCCCCCCCCCCC(O)CCCCCCCC ONNSSMGRFLULCC-UHFFFAOYSA-N 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- RNZYPFVHWLRVPJ-UHFFFAOYSA-N pentadecan-6-ol Chemical compound CCCCCCCCCC(O)CCCCC RNZYPFVHWLRVPJ-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4238223A DE4238223C1 (de) | 1992-11-12 | 1992-11-12 | Transdermales therapeutisches System zur Verabreichung von Physostigmin an die Haut und Verfahren zu dessen Herstellung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LTIP1469A LTIP1469A (en) | 1994-06-15 |
| LT3107B true LT3107B (en) | 1994-12-27 |
Family
ID=6472735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTIP1469A LT3107B (en) | 1992-11-12 | 1993-11-12 | Transdermal therapeutical system containing fizostigmine and preparation the same |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US5698216A (xx) |
| EP (1) | EP0667774B1 (xx) |
| JP (1) | JP3407073B2 (xx) |
| KR (1) | KR100254573B1 (xx) |
| CN (1) | CN1088457A (xx) |
| AT (1) | ATE156356T1 (xx) |
| AU (1) | AU684256B2 (xx) |
| CA (1) | CA2147274C (xx) |
| CZ (1) | CZ284008B6 (xx) |
| DE (2) | DE4238223C1 (xx) |
| DK (1) | DK0667774T3 (xx) |
| EE (1) | EE03135B1 (xx) |
| EG (1) | EG20527A (xx) |
| ES (1) | ES2105334T3 (xx) |
| FI (1) | FI952269A (xx) |
| GR (1) | GR3024720T3 (xx) |
| HR (1) | HRP931391B1 (xx) |
| HU (1) | HUT72963A (xx) |
| IL (1) | IL107547A (xx) |
| LT (1) | LT3107B (xx) |
| LV (1) | LV10749B (xx) |
| MD (1) | MD937C2 (xx) |
| MY (1) | MY111373A (xx) |
| NO (1) | NO306760B1 (xx) |
| NZ (1) | NZ257136A (xx) |
| PL (1) | PL172999B1 (xx) |
| RU (1) | RU2108812C1 (xx) |
| SI (1) | SI9300589A (xx) |
| SK (1) | SK280185B6 (xx) |
| WO (1) | WO1994010999A1 (xx) |
| YU (1) | YU71293A (xx) |
| ZA (1) | ZA938413B (xx) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4446600A1 (de) * | 1994-12-24 | 1996-06-27 | Lohmann Therapie Syst Lts | Transdermale Resorption von Wirkstoffen aus unterkühlten Schmelzen |
| DE19828273B4 (de) * | 1998-06-25 | 2005-02-24 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System, enthaltend Hormone und Kristallisationsinhibitoren |
| DE19923551A1 (de) * | 1999-05-21 | 2000-11-30 | Lohmann Therapie Syst Lts | Pharmazeutisches Präparat mit dem Wirkstoff Diamorphin und seine Verwendung in einem Verfahren zur Behandlung der Opiatsucht |
| AT500143A1 (de) * | 2004-04-22 | 2005-11-15 | Sanochemia Pharmazeutika Ag | Cholinesterase-inhibitoren in liposomen sowie deren herstellung und verwendung |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3921363A (en) | 1974-05-17 | 1975-11-25 | Preston Metal & Roofing Prod | Cross member with end connector |
| DE3528979A1 (de) | 1984-08-14 | 1986-02-27 | State Of Israel Represented By The Prime Minister's Office Israel Institute For Biological Research, Ness-Ziona | Arzneimittelfreigabesystem |
| DE3606892A1 (de) | 1985-03-05 | 1986-09-18 | Ciba-Geigy Ag, Basel | Pharmazeutische formulierungen und verfahren zur behandlung von gedaechtnisstoerungen |
| DE3843239C1 (xx) | 1988-12-22 | 1990-02-22 | Lohmann Therapie Syst Lts | |
| DE3843238C1 (xx) | 1988-12-22 | 1990-02-22 | Lohmann Therapie Syst Lts | |
| WO1991015176A1 (en) | 1990-04-06 | 1991-10-17 | Pharmetrix Corporation | Device and method for enhanced administration of physostigmine |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5350581A (en) * | 1989-12-14 | 1994-09-27 | Pharmetrix Corporation | Method for manufacturing transdermal devices |
| NZ237241A (en) * | 1990-03-02 | 1993-11-25 | Pharmetrix Corp | Method for increasing the storage stability of physostigmine |
| JP4355469B2 (ja) * | 2002-03-08 | 2009-11-04 | 日本碍子株式会社 | アルミナ担持担体、触媒体及びアルミナ担持担体の製造方法 |
-
1992
- 1992-11-12 DE DE4238223A patent/DE4238223C1/de not_active Expired - Lifetime
-
1993
- 1993-10-27 PL PL93308531A patent/PL172999B1/pl unknown
- 1993-10-27 NZ NZ257136A patent/NZ257136A/en unknown
- 1993-10-27 ES ES93923558T patent/ES2105334T3/es not_active Expired - Lifetime
- 1993-10-27 RU RU95113504A patent/RU2108812C1/ru active
- 1993-10-27 EP EP93923558A patent/EP0667774B1/de not_active Expired - Lifetime
- 1993-10-27 AU AU53385/94A patent/AU684256B2/en not_active Ceased
- 1993-10-27 US US08/433,459 patent/US5698216A/en not_active Expired - Lifetime
- 1993-10-27 JP JP51164994A patent/JP3407073B2/ja not_active Expired - Fee Related
- 1993-10-27 DE DE59307089T patent/DE59307089D1/de not_active Expired - Lifetime
- 1993-10-27 CZ CZ951244A patent/CZ284008B6/cs not_active IP Right Cessation
- 1993-10-27 WO PCT/EP1993/002970 patent/WO1994010999A1/de active IP Right Grant
- 1993-10-27 DK DK93923558.6T patent/DK0667774T3/da active
- 1993-10-27 AT AT93923558T patent/ATE156356T1/de active
- 1993-10-27 KR KR1019950701873A patent/KR100254573B1/ko not_active IP Right Cessation
- 1993-10-27 SK SK593-95A patent/SK280185B6/sk unknown
- 1993-10-27 HU HU9501390A patent/HUT72963A/hu unknown
- 1993-10-27 CA CA002147274A patent/CA2147274C/en not_active Expired - Fee Related
- 1993-11-05 LV LVP-93-1204A patent/LV10749B/lv unknown
- 1993-11-09 IL IL10754793A patent/IL107547A/en not_active IP Right Cessation
- 1993-11-10 YU YU71293A patent/YU71293A/sh unknown
- 1993-11-11 HR HRP4238223.8A patent/HRP931391B1/xx not_active IP Right Cessation
- 1993-11-11 MY MYPI93002363A patent/MY111373A/en unknown
- 1993-11-11 CN CN93112909A patent/CN1088457A/zh active Pending
- 1993-11-11 EG EG71993A patent/EG20527A/xx active
- 1993-11-11 SI SI9300589A patent/SI9300589A/sl unknown
- 1993-11-11 ZA ZA938413A patent/ZA938413B/xx unknown
- 1993-11-12 LT LTIP1469A patent/LT3107B/lt not_active IP Right Cessation
-
1994
- 1994-07-26 MD MD94-0311A patent/MD937C2/ro active IP Right Grant
- 1994-11-18 EE EE9400145A patent/EE03135B1/xx unknown
-
1995
- 1995-05-10 FI FI952269A patent/FI952269A/fi unknown
- 1995-05-11 NO NO951864A patent/NO306760B1/no not_active IP Right Cessation
-
1997
- 1997-09-16 GR GR970402363T patent/GR3024720T3/el unknown
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3921363A (en) | 1974-05-17 | 1975-11-25 | Preston Metal & Roofing Prod | Cross member with end connector |
| DE3528979A1 (de) | 1984-08-14 | 1986-02-27 | State Of Israel Represented By The Prime Minister's Office Israel Institute For Biological Research, Ness-Ziona | Arzneimittelfreigabesystem |
| DE3528979C2 (xx) | 1984-08-14 | 1989-12-07 | State Of Israel Represented By The Prime Minister's Office Israel Institute For Biological Research, Ness-Ziona, Il | |
| DE3606892A1 (de) | 1985-03-05 | 1986-09-18 | Ciba-Geigy Ag, Basel | Pharmazeutische formulierungen und verfahren zur behandlung von gedaechtnisstoerungen |
| DE3843239C1 (xx) | 1988-12-22 | 1990-02-22 | Lohmann Therapie Syst Lts | |
| DE3843238C1 (xx) | 1988-12-22 | 1990-02-22 | Lohmann Therapie Syst Lts | |
| WO1991015176A1 (en) | 1990-04-06 | 1991-10-17 | Pharmetrix Corporation | Device and method for enhanced administration of physostigmine |
Non-Patent Citations (2)
| Title |
|---|
| HEILMANN KLAUS: "Terapinės sistemos" |
| VOIGT RUDOLF: "Lehrbuch der pharmazeutischen Technologie", pages: 352 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR950015058B1 (ko) | 활성 성분으로 피소스티그민을 함유하는 경피 치료 시스템 및 그 제조방법 | |
| RU2176499C2 (ru) | Композиция для чрескожного введения стероидных лекарственных средств и содержащий ее препарат | |
| KR100300477B1 (ko) | 활성성분으로서 갈란타민을 포함하는 경피치료시스템 | |
| JP2655983B2 (ja) | チロシナーゼ抑制活性を有する薬物の安定性を改善する方法、及び、皮膚美白用貼付剤 | |
| US8962014B2 (en) | Transdermal therapeutic system for administering rivastigmine or derivatives thereof | |
| HRP930675A2 (en) | Process for the production of a transdermal therapeutic system containing buprenorphine as an active component | |
| NZ209843A (en) | Transdermal delivery system for administration of nitroglycerin | |
| LT3107B (en) | Transdermal therapeutical system containing fizostigmine and preparation the same | |
| WO2021098791A1 (zh) | 一种含有美金刚的透皮贴剂 | |
| JP3980634B2 (ja) | 活性物質モルフィン−６−グルクロニドを含む全身的経皮投与用医薬組成物 | |
| EP1043979B1 (en) | Compositions for the transdermal and dermal administration of biologically active agents | |
| JPH02196714A (ja) | 経皮吸収貼付剤 | |
| JPH02102656A (ja) | 経皮吸収貼付剤 | |
| DK202201037A1 (en) | Slow-release medical plaster | |
| KR20020066047A (ko) | 케토프로펜을 함유하는 경피투여 조성물과 이를 포함하는매트릭스형 경피투여 첩부제 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM9A | Lapsed patents |
Effective date: 20011112 |